<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321161</url>
  </required_header>
  <id_info>
    <org_study_id>BICARB_AMLrelapse</org_study_id>
    <nct_id>NCT04321161</nct_id>
  </id_info>
  <brief_title>Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment</brief_title>
  <official_title>Analysis of T Cell Metabolism and Immune Phenotype in Relapsed Acute Myeloid Leukemia Patients Receiving Donor Lymphocyte Infusions and Bicanorm (Sodium Bicarbonate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium
      bicarbonate) were analyzed including T cell metabolism and immune phenotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myeloid leukemia (AML) patients suffering from relapse after allogeneic hematopoietic
      cell transplantation (allo-HCT) have a poor survival outcome. Donor lymphocyte infusions
      (DLIs) to induce graft-versus-leukemia (GvL) effects have a limited survival benefit.

      Extensive preclinical studies have shown a beneficial effect of sodium bicarbonate on
      metabolic fitness of leukemia-reactive T cells in GvL AML models. Therefore, the
      investigators aimed to investigate a potential benefit of Bicanorm (Sodium bicarbonate)
      treatment accompanying DLIs in relapsed AML patients. The investigators determined the
      metabolic and immune phenotype of T cells isolated from patients receiving DLIs before and
      after Bicanorm (Sodium bicarbonate) treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Actual">March 18, 2020</completion_date>
  <primary_completion_date type="Actual">March 18, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T cell glycolytic activity</measure>
    <time_frame>2 months</time_frame>
    <description>Extracellular acidification rate (ECAR) determined by live-cell metabolic assay using the Seahorse Analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell respiratory activity</measure>
    <time_frame>2 months</time_frame>
    <description>Oxygen consumption rate (OCR) determined by live-cell metabolic assay using the Seahorse Analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell phenotype</measure>
    <time_frame>2 months</time_frame>
    <description>T cell cytokine and effector molecule production determined by flow cytometric analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum pH</measure>
    <time_frame>2 months</time_frame>
    <description>Measurement of serum pH</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myeloid Leukemia, in Relapse</condition>
  <arm_group>
    <arm_group_label>AML relapse under DLI and Bicanorm treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Analysis of T cell metabolism, immune phenotype and serum pH before and after Bicanorm (Sodium bicarbonate) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicanorm</intervention_name>
    <description>Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.
sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)</description>
    <arm_group_label>AML relapse under DLI and Bicanorm treatment</arm_group_label>
    <other_name>Sodium bicarbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed AML relapse after allo-HCT

          -  patients receiving DLIs

          -  age ≥ 18 years

          -  written informed consent

          -  ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          -  age &lt; 18 years

          -  lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University of Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.</citation>
    <PMID>26321679</PMID>
  </reference>
  <reference>
    <citation>Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 May 1;77(9):2552.</citation>
    <PMID>26719539</PMID>
  </reference>
  <reference>
    <citation>Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V; EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007 Nov 1;25(31):4938-45. Epub 2007 Oct 1.</citation>
    <PMID>17909197</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Director of the Division of Tumor Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

